Eficacia del esquema FIGO para el manejo médico del aborto en el primer trimestre

Cintia María Sepúlveda Rivera; Osvaldo Miranda Araujo; Jessica Aideé Mora Galván; Arturo Maximiliano Ruiz Beltrán; Diego Arturo González Vásquez; Jefsi Argelia León Domínguez

doi:10.31403/rpgo.v66i2186

Authors

Cintia María Sepúlveda Rivera Department of Obstetrics; Instituto Nacional de Perinatología, Mexico City, Mexico
Osvaldo Miranda Araujo Department of Obstetrics; Instituto Nacional de Perinatología, Mexico City, Mexico
Jessica Aideé Mora Galván Department of Obstetrics; Instituto Nacional de Perinatología, Mexico City, Mexico
Arturo Maximiliano Ruiz Beltrán Department of Internal Medicine; Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Diego Arturo González Vásquez Department of Obstetrics; Instituto Nacional de Perinatología, Mexico City, Mexico
Jefsi Argelia León Domínguez Department of Obstetrics; Instituto Nacional de Perinatología, Mexico City, Mexico

DOI:

https://doi.org/10.31403/rpgo.v66i2186

Abstract

Objective: To determine the effectiveness of misoprostol using the International Federation of Gynecology and Obstetrics (FIGO) 2017 protocol for medical management of first trimester abortion. Methods: A cross-sectional study was performed between March and September 2018. Seventy-six patients diagnosed with first trimester spontaneous abortion were managed following the FIGO 2017 protocol for medical management of first trimester abortion. Results: Main indications for inclusion of the 76 patients were missed abortion 57.9%, incomplete abortion 25%, and anembryonic pregnancy 17.1%. Medical induction with misoprostol followed the FIGO 2017 protocol for medical management of first trimester abortion. The most frequent side effect reported was abnormal uterine bleeding associated with pelvic pain (72.3% of patients). Complete uterine evacuation was accomplished in 98.6% of the patients. Conclusion: Misoprostol use in patients with first trimester abortion following the FIGO 2017 protocol was a safe and cost-effective therapeutic option.